Amanda Wagner, Immunitas CEO

Out to prove the next big I/O tar­get, Im­mu­ni­tas' chief deal­mak­er steps up to CEO role

To Aman­da Wag­n­er, the past two years or so she’s spent at Im­mu­ni­tas feels like a mi­cro­cosm of her en­tire ca­reer up to now.

Trained in neu­ro­science and equipped with an MBA, Wag­n­er’s 16-year bio­phar­ma ca­reer could be split in­to a first half in R&D and a sec­ond in cor­po­rate fi­nance and busi­ness de­vel­op­ment. She was con­sult­ing for the Long­wood Fund in 2019 when the VC firm pulled her aside to talk about a new im­muno-on­col­o­gy com­pa­ny it was in­cu­bat­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.